AKI
Beyond's analysis on AKI
- — BioPorto launches first patient enrollment in US validation study for its ProNephro AKI NGAL biomarker test, advancing commercialization of a rapid acute kidney injury diagnostic
- — PenKid biomarker provides decision support for kidney replacement therapy in critically ill patients, addressing an unmet clinical need
Recent news mentioning AKI
- — OpenAI and Anthropic are making 10 times more revenue than all Chinese AI models combined, research group Rhodium says
- — Making the Most of Every Ray, Powering the Unpowered: 2026 Global Low-Carbon Industry Forum Explores Pathways to Bridge the Electricity Gap
- — AS-i Pro Kapital Grupp võlakirjade märkimise viimane päev on homme
- — Tokyo Metropolitan Government Launches Inbound Tourism Website Developed by TCVB to Connect Tokyo and Northern Kanto Prefectures of Ibaraki, Tochigi and Gunma
- — Sanitas paga casi 4 millones a su ex CEO Iñaki Peralta
- — Boeing CEO: 737 Max production taking 'a little bit longer' to stabilize than expected
- — Tony Lama Debuts Men's Apparel: Taking the Brand Beyond the Boot
- — Tornator Oyj laskee liikkeeseen 300 miljoonan euron vihreän joukkovelkakirjalainan
- — Happy Money's 2026 Credit Check-In Reveals Growing Divide in Americans' Financial Progress and the Influence of AI in Financial Decision-Making
- — A Bear Market Is Coming. History Says the Smartest Investors Are Already Making This 1 Move
- — Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
- — S-Pankki Oyj täydentää 16.7.2026 päivättyä tarjousasiakirjaa koskien tekemäänsä vapaaehtoista julkista käteisostotarjousta kaikista Oma Säästöpankki Oyj:n osakkeista